bioRxivSynthetic BiologyPreprint
Discovery of tREP-18, a novel class of tRNA encoded peptide with potent leishmanicidal activity
Amrita Chakrabarti, Monika KaushikiD, Juveria Khan, Deepanshu Soota, Ponnuusamy Kalairasan, Sunil Kumar SainiiD, Siddharth Manvati, Jhalak SinghaliD, Anand RanganathaniD, Soumya PatiiD, Pawan Kumar DhariD, Shailja SinghiD
Abstract
In the post genomic era, tRNA-derived fragments have emerged as a new class of non-coding gene regulators, those play crucial roles both at the transcriptional and translational levels, in different cellular biogenesis. However, none of the studies has ever asked whether tRNAs can also be translated into peptides with any biological significance. Thus, we present a novel hypothesis which suggested that; design and synthesis of tRNA-derived peptides from prokaryotic genome can be exploited for developing unique chemotherapeutics against neglected tropical diseases, like Visceral leishmaniasis (VL) and its aggressive form known as post kalazar dermal leishmaniasis (PKDL). To achieve this aim, we have used a novel system biology-based strategy, which involved; i) mining of unique tRNAs from E. coli genome and their translation into peptide in silico, ii) designing of theoretical 3D models to evaluate their stability, iii) prediction of their biological activity by screening against anti-parasitic database to filter the lead peptide. Based on this strategy, a unique tRNA-derived peptide (tREP-18) was selected, chemically synthesized, and used in vitro for elucidating its therapeutic significance against L. donovani, a causative agent of VL and PKDL. Our findings demonstrated that, tREP-18 can impose high level toxicity to L. donovani promastigotes, by disrupting the ultrastructural cellular architect, destabilizing the mitochondrial membrane potential ({Delta}{Psi}m), thus leading to drastic reduction in cell viability and proliferation. It also imparted high level of toxicity to BS12 a clinical isolate of PKDL. Conceivably, we for the first time reports a novel tRNA-derived peptide "tREP18" with excellent anti-leishmanial property, which can be further utilized for developing it as antileishmanial drug. One Sentence SummaryHere we report a novel first-in-class tRNA encoded peptide and its super anti-leishmanial characteristics.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lead optimization against drug-resistant Leishmania donovani infection: Semi-synthetic derivatives of ethyl linoleate isolated from Indian edible mushroom Meripilus giganteus.
Supriya Nath, Karan Chhetri, … Chiranjib Pal·bioRxiv·Jul 3, 2025
- Targeting tRNA-Synthetase Interactions towards Novel Therapeutic Discovery Against Eukaryotic Pathogens
P. Kelly, F. Hadi-Nezhad, … D. H. Ardell·bioRxiv·Jul 23, 2019
- Identification of Leishmania donovani inhibitors from pathogen box compounds of Medicine for Malaria Venture
M. Tadele, S. M. Abay, … A. Hailu·bioRxiv·Jul 26, 2019
- The bacterial leader peptide peTrpL has a conserved function in antibiotic-dependent posttranscriptional regulation of ribosomal genes
H. Melior, S. Maass, … E. Evguenieva-Hackenberg·bioRxiv·Sep 26, 2019
- Discovery of Host-Directed Small Molecules with Broad Anti-Leishmanial Efficacy
Elizabeth G. Graham-Gurysh, M. Shamim Hasan Zahid, … Kristy M. Ainslie·bioRxiv·Nov 4, 2025
- The impact of knocking out the Leishmania major telomerase RNA (LeishTER): from altered cell proliferation to decreased parasite infectivity
Beatriz C. D. de Oliveira, Mark Ewusi Shiburah, … Maria Isabel Nogueira Cano·bioRxiv·Nov 10, 2023